ATTR-CM
Phase 3Small molecule
ATTR-CM is one of 24 small molecule programs targeting Amyloidosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Amyloidosis
#DrugCompanyPhaseTrials
1Soriatane
GSKApproved
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Approved
Decadron
AAspen Global Incorporated
Phase 3
Xeljanz
PPrism Pharmaceuticals
Approved
Darzalex
Johnson & JohnsonPhase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Attruby
NNavire Pharma Inc., a BridgeBio company
Phase 3
Venclexta
AbbViePhase 2
Belamaf
GSKPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Unspecified1 trial
Clinical Study of ATTR-CM
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04935021·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ATTR-CM. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details